Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Pulmocide Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
-
Lazard to Announce Fourth-Quarter and Full-Year 2024 Financial Results
-
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
-
PAR Technology Corporation to Participate at the 27th Annual Needham Growth Conference
-
Wealth Enhancement Announces Acquisition of Danison & Associates, Inc., an Independent RIA with Over $82 Million in Client Assets
-
Enveda Welcomes Jason Kim as Chief Financial Officer
-
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
-
VIPR Solutions dominates the Lloyd’s Market with three new insurer customers
-
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformati
-
Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration
-
WisdomTree Reports Monthly Metrics for December 2024
-
Terremoto Biosciences Appoints James Christensen, Ph.D., as President and Head of Research & Development
-
Regal Rexnord Corporation to Host Fourth Quarter 2024 Earnings Conference Call on Thursday, February 6, 2025
-
Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer
-
Revvity Announces FDA Clearance for First Automated Free Testosterone Test
-
Powerfleet to Present at the 27th Annual Needham Growth Conference
-
Serna Bio Announces Scientific Advisory Board
-
Tanger Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
-
Arrivo BioVentures Announces Positive Results from qEEG and BNA™ Study of SP-624 on Neural Brain Activity Related to Depression and Cognition
-
Addgene Expands Viral Vector Service with Packaged on Request
-
Savers Value Village, Inc. Announces Preliminary Fourth Quarter and Full Year Net Sales and Participation in the 27th Annual ICR Conference
-
SIXT USA Announces New Car Rental Branch at Louis Armstrong New Orleans International Airport
-
Leonardo DRS Schedules Fourth Quarter 2024 and Full Year 2024 Earnings Conference Call for February 20, 2025
-
Kardigan Launches with Industry-Leading Team to Modernize Cardiovascular Drug Development with Late-Stage Portfolio of Personalized Medicines
-
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
-
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
-
Genius Group increases Bitcoin Treasury to $35 million, ahead of schedule towards $120 million target.
-
BullFrog AI to Present at Biotech Showcase and RESI JPM During JP Morgan Week
-
Thumzup Media Corporation Offers $10,000 in Credits for Small Businesses to Support Recovery Efforts Following Los Angeles Wildfires
-
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
-
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones
-
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
-
Netcapital Announces Exercise of Warrants
-
Horizon Aircraft Signs Letter of Intent with Discovery Air Chile Ltda., Expanding Global Presence of Cavorite X7 Hybrid eVTOLs
-
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
-
Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine
-
Portillo’s Adds Industry Veteran Jack Hartung to Board of Directors
-
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
-
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
-
Heritage Distilling Introduces Bitcoin Treasury Policy Statement
-
Compass Diversified Holdings Announces Amendment of its Credit Agreement
-
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
-
ADDITIONAL RESULTS FROM THE LAPON CANYON PROJECT A NEVADA CANYON OWNED ROYALTY
-
Monster Beverage Announces Webcast Details For Investor Meeting/Business Update January 21, 2025
-
Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference
-
Cellebrite to Report Fourth-Quarter and Fiscal Year 2024 Financial Results on February 13, 2025
-
Veritex Holdings, Inc. Announces Dates of Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
-
MIND CTI to Acquire Aurenz GmbH
-
Westwood Announces Monthly Income Distributions for Westwood Salient Enhanced Midstream Income ETF (MDST) and Westwood Salient Enhanced Energy Income ETF (WEEI)
-
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
